Authors

• Hui Lin (ORCID: https://orcid.org/0000-0003-1278-4351)
• Miao He (ORCID: https://orcid.org/0000-0003-2385-794X)
• Yuchun Men
• Xiaohong Zhu (ORCID: https://orcid.org/0000-0003-3364-258X)
• Junyou Ge (ORCID: https://orcid.org/0000-0002-6524-0078)
• Ping Feng (ORCID: https://orcid.org/0000-0001-5488-0814)
• Man Chen (ORCID: https://orcid.org/0000-0001-7030-9968)
• Yue Cheng (ORCID: https://orcid.org/0000-0003-4697-4081)
• Bingjie Wu (ORCID: https://orcid.org/0009-0001-4843-0777)
• Yezhe Cheng
• Zhihui Liu (ORCID: https://orcid.org/0009-0007-4553-0098)
• Huifang Wang (ORCID: https://orcid.org/0000-0003-0305-2861)
• Shuangqing Du (ORCID: https://orcid.org/0000-0002-6417-2341)
• Xiaoping Jin
• Ying Wang (ORCID: https://orcid.org/0000-0002-2571-9367)

Institutions

• Target (United States) (US)
• National Medical Products Administration (CN)
• Sichuan University (CN)
• West China Hospital of Sichuan University (CN)
• BioEnergetics (United States) (US)
• Kelun Group (China) (CN)

Publication Details

Journal

Expert Opinion on Investigational Drugs

Published

2025-12-02

DOI

https://doi.org/10.1080/13543784.2025.2599454

Primary Topic

Rheumatoid Arthritis Research and Therapies

Type

article

Field-Weighted Citation Impact

0.00